Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Multidisciplinary Collaboration Is Vital for Timely, Definitive Diagnosis of Indolent Systemic Mastocytosis

February 26th 2025

Andrew Kuykendall, MD, discusses the importance of a nuanced, multidisciplinary approach to expedite the diagnosis of indolent systemic mastocytosis.

Orca-Q Delivers Early Evidence of GVHD Risk Mitigation in Hematologic Malignancies

February 26th 2025

Amandeep Salhotra, MD, discusses data that have demonstrated the anti-GVHD activity of post-transplant Orca-Q in patients with hematologic malignancies.

Data Continue to Reshape Treatment Considerations Across Advanced GI Malignancies

February 25th 2025

Mohammed Najeeb Al Hallak, MD, MS explores treatment considerations in advanced pancreatic, colorectal, and neuroendocrine cancers.

Isatuximab Plus VRd Wins Japanese Approval for Newly Diagnosed Myeloma

February 25th 2025

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

FDA Grants Priority Review to Perioperative Pembrolizumab in Resectable HNSCC

February 25th 2025

The FDA has granted priority review to the sBLA for perioperative pembrolizumab plus adjuvant radiotherapy in resectable locally advanced HNSCC.

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

February 24th 2025

Pedro Barata, MD, discusses the expansion of radioligand therapies and the identification of novel targets beyond PSMA in prostate cancer.

Orca-T Promotes T-Cell Activation in Hematologic Malignancies

February 24th 2025

Cameron S. Bader, PhD, discusses findings from a study evaluating the prevalence of FOXP3 and Helios expression in Orca-T recipients.

Strategic and Safe Lorlatinib Use Is Key to Optimal ALK+ NSCLC Management

February 21st 2025

D. Ross Camidge, MD, PhD, discusses ways that ALK-positive NSCLC management has changed based on 5-year follow-up data with lorlatinib in the CROWN trial.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Dr Harrison on Investigational JAK Inhibitor–Based Combinations in Myelofibrosis

February 21st 2025

Claire Harrison, MD, FRCP, FRCPath, discusses ongoing research with first-line JAK inhibitors for patients with myelofibrosis.

Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

February 21st 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses patient-specific factors to consider during the selection of frontline systemic therapy for HCC.

Dr Fox on the Design of the TERZO Trial of Duvelisib in R/R Nodal T-Cell Lymphoma

February 20th 2025

Christopher P. Fox, PhD, MBChB(Hons), FRCP FRCPath, discusses the TERZO trial investigating duvelisib in relapsed/refractory nodal T-cell lymphoma.

Epcoritamab Gains Japanese Approval for R/R Follicular Lymphoma

February 20th 2025

The Ministry of Health, Labour, and Welfare in Japan has approved epcoritamab for relapsed or refractory follicular lymphoma.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

67Cu-SAR-bisPSMA Earns FDA Fast Track Designation for PSMA+ mCRPC

February 20th 2025

The FDA granted fast track designation to 67Cu-SAR-bisPSMA for PSMA-positive metastatic castration-resistant prostate cancer.

FDA Grants Breakthrough Therapy Designation to Petosemtamab Plus Pembrolizumab for PD-L1+ HNSCC

February 20th 2025

Petosemtamab/pembrolizumab received FDA breakthrough therapy designation for PD-L1–positive recurrent/metastatic head and neck squamous cell carcinoma.

JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management

February 19th 2025

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma

February 19th 2025

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

FDA Grants Priority Review to Zongertinib for HER2-Mutant Advanced NSCLC

February 19th 2025

The FDA has granted priority review to zongertinib for unresectable or metastatic HER2-mutant advanced NSCLC.

Neoadjuvant Nivolumab Plus Chemo Improves OS in Resectable NSCLC

February 19th 2025

Neoadjuvant nivolumab plus chemotherapy improved overall survival in resectable non–small cell lung cancer.